|
Canada-0-LIBRARIES कंपनी निर्देशिकाएँ
|
कंपनी समाचार :
- Improving Clinical Trials of Drugs to Treat Schizophrenia
Currently, the standard clinical trial to assess the efficacy of a drug to treat schizophrenia lasts for six weeks after the onset of treatment, and patients are interviewed weekly by a
- EMA and FDA psychiatric drug trial guidelines: assessment of guideline . . .
The 13 EMA guidelines were published between 2005 and 2017; the panic disorder guideline could not be downloaded All EMA guidelines were adopted (i e final) versions, two (insomnia and schizophrenia) had been revised once, and the depression guideline had been revised twice
- Guideline on clinical investigation of medicinal products, including . . .
This document is intended to provide general guidance for the development of medicinal products, including depot preparations, for the treatment of schizophrenia The guideline has been developed during a transitional period in which the DSM IV classification and diagnostic criteria for schizophrenia
- Once-a-week pill for schizophrenia shows promise in clinical trials
In a new paper, Prof Giovanni Traverso and his colleagues highlight the results of a clinical trial that showed “a pill taken just once a week, gradually releasing medicine from within the stomach, can greatly simplify the drug schedule faced by schizophrenia patients,” writes Dennis Thompson for HealthDay News “These final-stage clinical trial results are the product of more than 10
- Clinical Guidance on the Identification and Management of . . . - PubMed
With increased awareness, those involved in the care of patients with schizophrenia will be able to identify TRS earlier in its course, thus supporting more informed treatment decisions by clinicians, patients, and caregivers to reduce the overall disease burden
- CLINICAL TRIAL PROTOCOL
The primary objectives of this trial are to provide proof of clinical concept (PoCC) and dose finding data in patients with schizophrenia on stable antipsychotic treatment who are treated with oral once daily administration of BI 425809 or placebo Other objectives of this trial are to assess the safety of BI 425809
- Schizophrenia: Four major clinical trials to watch in 2023
Novel mechanisms and an overlooked symptom target highlight a slate of major schizophrenia clinical trials with readouts expected in 2023 Despite significant advances in understanding the neurobiology of schizophrenia, treatment options have largely remained limited
- MIT’s Once-a-Week Pill Could Revolutionize Schizophrenia Treatment
In a phase 3 clinical trial led by MIT spinout Lyndra Therapeutics, the researchers tested the once-weekly pill using a commonly prescribed medication for managing schizophrenia symptoms They found that the weekly treatment maintained steady drug levels in patients’ bodies and was just as effective at controlling symptoms as the traditional
- New Developments in the Treatment of Schizophrenia: An Expert . . .
New therapies in development that do not directly target dopamine receptors and have demonstrated robust efficacy in phase 2 and 3 clinical trials, with signals of efficacy for negative and possibly also cognitive symptoms, represent a potential paradigm shift in the treatment of schizophrenia
|
|